The IPO Buzz: Scribe Therapeutics (SCTX Proposed) Sets Terms for $100 Million IPO
Scribe Therapeutics (SCTX Proposed), an Eli Lilly-backed Phase 1 biotech developing drugs to lower cholesterol and triglyceride levels, launched its $100.1 million IPO early today – with plans to price it later this week. The company, based in Alameda, California, is offering 7.15 million shares at a price range of $13.00 to $15.00 to raise […]
July 20, 2026 Read More